NPC Archive Item: Glitazone use associated with pneumonia in a meta-analysis

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 16 June 2011 This meta-analysis of 13 RCTs (n=17,627) found the use of glitazones was associated with an increased risk of pneumonia or lower respiratory tract infection (LRTI) in […]

NPC Archive Item: Olmesartan reduces disease oriented outcomes but may have potential cardiovascular safety concerns

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 28th March 2011 The ROADMAP trial found olmesartan delayed the onset of microalbuminuria in patients with type 2 diabetes and normoalbuminuria. While this disease-oriented outcome (DOO) suggested a potential benefit […]

NPC Archive Item: More evidence for self-monitoring of blood glucose in type 2 diabetes?

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 22nd February 2011 A study has found that a structured self-monitoring of blood glucose intervention package improved glycaemic control compared with enhanced usual care in patients with poorly controlled type […]

NPC Archive Item: Is pioglitazone▼ associated with an increased cardiovascular risk similar to rosiglitazone?

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 16 December 2010 Rosiglitazone was withdrawn from clinical use across Europe because of concerns over excess cardiovascular (CV) risk. This cohort study found that pioglitazone▼ was associated with the […]

NPC Archive Item: NICE guidance on liraglutide▼ for type 2 diabetes

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 11 November 2010 NICE has issued guidance on the use of liraglutide▼ for the treatment of type 2 diabetes. Liraglutide 1.2mg is a dual therapy option only in very limited […]

NPC Archive Item: Does intensive blood glucose control reduce microvascular outcomes in type 2 diabetes? Results from ACCORD

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 21 October 2010 An analysis of the ACCORD study has found that intensive blood glucose control did not reduce composite advanced microvascular outcomes (renal complications, eye complications or peripheral […]

NPC Archive Item: Rosiglitazone: withdrawal from clinical use

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 24 September 2010 Suspension of marketing authorisations for rosiglitazone (Avandia® and the combination product with metformin, Avandamet®) has been recommended by the European Medicines Agency (EMA), following concerns over excess […]

NPC Archive Item: Are higher doses of insulin glargine associated with cancer?

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 13 July 2010 New data show that insulin glargine is not associated with an increase in cancer (07/08/12) Since these materials were published, ORIGIN (2012), a 6-year randomised controlled trial, has […]

NPC Archive Item: A key message on intensive blood-pressure control in type 2 diabetes mellitus from ACCORD

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 20 April 2010 The ACCORD blood-pressure (BP) study conducted in patients with type 2 diabetes at high risk for cardiovascular (CV) disease concluded that intensive BP control to a target […]

NPC Archive Item: Fenofibrate does not reduce CV events in patients with type 2 diabetes when added to simvastatin

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 22 April 2010 The ACCORD lipid trial in patients with type 2 diabetes concluded that intensifying lipid modification therapy through combination use of fenofibrate and simvastatin (at a daily […]